On Wednesday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), gained 4.29% to $106.96.
Gilead Sciences, declared detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary arterial hypertensION). In AMBITION, conducted in partnership with GlaxoSmithKline (GSK), combination therapy with Letairis (ambrisentan) and tadalafil reduced the risk of clinical failure by 50 percent contrast to the pooled Letairis and tadalafil monotherapy arm (hazard ratio = 0.50; 95 percent CI: 0.35, 0.72; p<0.001). These data were published in The New England Journal of Medicine.
Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States (U.S.), the European Union (EU) and other countries as once-daily treatments for patients with pulmonary arterial hypertension (PAH) (WHO Group 1) with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris® to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is presently not approved.
“The only other published, large-scale, event-driven study to date in PAH contrast an endothelin receptor antagonist to placebo in patients who were either treatment-naïve or on background therapy, however, all patients in AMBITION received an approved therapy for PAH,” said Lewis J. Rubin, MD, Emeritus Professor, University of California, San Diego and Co-Chair of the AMBITION Steering Committee. “Thus, the magnitude of the effect with this combination in comparison to active monotherapy is impressive, particularly in WHO functional class II patients where we observed nearly an 80 percent reduction in risk of clinical failure as compared to monotherapy.”
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Shares of Devon Energy Corp (NYSE:DVN), inclined 4.94% to $38.44, during its last trading session.
Devon Energy Corp., declared that Dave Hager, president and chief executive officer, will present at the Barclays CEO Energy-Power Conference in New York City on Wednesday, Sept. 9, 2015, at 9:05 a.m. ET (8:05 a.m. CT).
Devon Energy Corporation, an independent energy company, primarily engages in the exploration, development, and production of oil, natural gas, and natural gas liquids (NGLs) in the United States and Canada. It holds interests in various properties located in Anadarko Basin, Barnett Shale, Eagle Ford, Mississippian-Woodford Trend, Permian Basin, and Rockies in the United States, in addition to in the Jackfish and Pike heavy oil projects located in Alberta, Canada.
Finally, Hyatt Hotels Corporation (NYSE:H), ended its last trade with 3.97% gain, and closed at $51.08.
Hyatt Place Buffalo/Amherst, the first Hyatt Place in Western New York, is officially open in Amherst, N.Y. The hotel brings the Hyatt Place brand’s intuitive design, casual atmosphere, and practical amenities, such as free Wi-Fi and 24-hour food offerings, to the Buffalo area.
Located on Main Street, directly off Interstate 290, Hyatt Place Buffalo/Amherst is central to all of Buffalo’s main attractions. The attractive, beautifully landscaped hotel is less than five miles from Buffalo Niagara International airport, the University at Buffalo, and two of Buffalo’s largest malls. The hotel is about a 20-minute drive to Niagara Falls, Ralph Wilson Stadium, home of the Buffalo Bills, and First Niagara Center, home of the Buffalo Sabres. A number of family-friendly activities are also nearby, counting the Aquarium of Niagara, the Buffalo Zoological Gardens, and Six Flags Darien Lake, which is less than 30 minutes away. Hyatt Place Buffalo/Amherst is also within walking distance to the village of Williamsville and hamlet of Snyder, offering guests a variety of shops and restaurants, in addition to the picturesque setting of Glen Falls.
“As Buffalo continues to grow and thrive economically, we are excited to add to the momentum by welcoming the first Hyatt Place hotel to the area,” said General Manager David Zeplowitz. “With our smartly designed social spaces and guestrooms with separate areas to work and sleep, Hyatt Place Buffalo/Amherst offers multitasking travelers the room they need to spread out, and our free hot breakfast is just the thing to get our guests going in the morning.”
Hyatt Hotels Corporation, a hospitality company, develops, owns, operates, manages, franchises, licenses, or provides services to full and select service hotels, resorts, and residential and vacation properties worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
